Livoletide
- Generic Name
- Livoletide
- Drug Type
- Small Molecule
- Chemical Formula
- C40H63N15O13
- CAS Number
- 1088543-62-7
- Unique Ingredient Identifier
- 9VHD7J6363
- Background
Livoletide is under investigation in clinical trial NCT03790865 (Effects of Livoletide (AZP-531) on Food-related Behaviors in Patients With Prader-Willi Syndrome).
Effects of Livoletide (AZP-531) on Food-related Behaviors in Patients With Prader-Willi Syndrome
Phase 2
Terminated
- Conditions
- Prader-Willi SyndromeHyperphagia
- Interventions
- Drug: Placebo
- First Posted Date
- 2019-01-02
- Last Posted Date
- 2021-02-17
- Lead Sponsor
- Millendo Therapeutics SAS
- Target Recruit Count
- 158
- Registration Number
- NCT03790865
- Locations
- 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇫🇷Centre Hospitalier Universitaire d'Angers, Angers, France
🇺🇸Winthrop University Hospital, Mineola, New York, United States
A Study to Evaluate AZP531 in Healthy Volunteers, Overweight/Obese Volunteers and Patients With Type 2 Diabetes Mellitus
- First Posted Date
- 2014-01-20
- Last Posted Date
- 2015-06-18
- Lead Sponsor
- Alizé Pharma
- Target Recruit Count
- 108
- Registration Number
- NCT02040012
- Locations
- 🇬🇧
Quintiles Drug Research Unit at Guy's Hospital, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath